Top

Published in:

01-11-2008 | Original Article

Interleukin-6 protects against paclitaxel, cisplatin and vincristine-induced neuropathies without impairing chemotherapeutic activity

Authors: Noelle Callizot, Emile Andriambeloson, Jonathan Glass, Michel Revel, Pamela Ferro, Rocco Cirillo, Pierre-Alain Vitte, Michel Dreano

Published in: Cancer Chemotherapy and Pharmacology | Issue 6/2008

Abstract

Purpose

This study was conducted to investigate the potential neuroprotective effect of IL-6 on chemotherapy induced neuropathy (CIN). IL-6 was compared to four-methylcatechol (4-MC)-a known inducer of NGF secretion previously shown to exhibit neuroprotective effects in CIN models.

Methods

Three CIN models were used; two in rats (cisplatin and vincristine) and one in mice (paclitaxel). IL-6 was delivered in four different doses in rats (0.3, 1, 3, 10 μg/kg, sc) every day from the first day of chemotherapeutic agent intoxication until the end of the study (day 37 for cisplatin protocol and day 30 for vincristine procedure). In mice, IL-6 was delivered at 10 μg/kg, sc either daily or three times a week from the first day of intoxication until the end of the study (day 19). Behavioral testings (hot plate and rotarod), nerve conduction studies (CMAP, SNCV, H-wave) and histo-morphometric analysis were done for all models. In addition, we tested whether IL-6 interfered with the tumor-reducing effects of the chemotherapeutic agents.

Results

IL-6 treatment prevented the behavioral and electrophysiological abnormalities produced by vincristine, cisplatin and Taxol intoxication, and similarly prevented the pathological changes in peripheral nerves. The neuroprotective action of chronic IL-6 treatment was at least equal to that of 4-MC. In addition, IL-6 neither inhibited the antitumour activity of cisplatin, nor stimulated tumour growth.

Conclusion

IL-6 at low doses (10 μg/kg) provided protection against the development of CIN without demonstrating interference with the anti tumoural activity of these anti-mitotic drugs.

Akaneya Y, Takahashi M, Hatanaka H (1995) Interleukin-1 beta enhances survival and interleukin-6 protects against MPP+ neurotoxicity in cultures of fetal rat dopaminergic neurons. Exp Neurol 136:44–52PubMedCrossRef

Andriambeloson E, Baillet C, Vitte PA, Garotta G, Dreano M, Callizot N (2006) Interleukin-6 attenuates the development of experimental diabetes-related neuropathy. Neuropathology 26:32–42PubMedCrossRef

Apfel SC (1996) Neurotrophic factors in the treatment of neurotoxicity: an overview. Neurotoxicology 17:839–844PubMed

Apfel SC, Arezzo JC, Lipson L, Kessler JA (1992) Nerve growth factor prevents experimental cisplatin neuropathy. Ann Neurol 31:76–80PubMedCrossRef

Bazan JF (1991) Neuropoietic cytokines in the hematopoietic fold. Neuron 7:197–208PubMedCrossRef

Bensadoun JC, de Almeida LP, Dreano M, Aebischer P, Deglon N (2001) Neuroprotective effect of interleukin-6 and IL6/IL6R chimera in the quinolinic acid rat model of Huntington’s syndrome. Eur J Neurosci 14:1753–1761PubMedCrossRef

Bolin LM, Verity AN, Silver JE, Shooter EM, Abrams JS (1995) Interleukin-6 production by Schwann cells and induction in sciatic nerve injury. J Neurochem 64:850–858PubMedCrossRef

Boucher TJ, Okuse K, Bennett DL, Munson JB, Wood JN, McMahon SB (2000) Potent analgesic effects of GDNF in neuropathic pain states. Science 290:124–127PubMedCrossRef

Boyle FM, Wheeler HR, Shenfield GM (1996) Glutamate ameliorates experimental vincristine neuropathy. J Pharmacol Exp Ther 279:410–415PubMed

10.

Boyle FM, Wheeler HR, Shenfield GM (1999) Amelioration of experimental cisplatin and paclitaxel neuropathy with glutamate. J Neurooncol 41:107–116PubMedCrossRef

11.

Callizot N, Warter JM, Poindron P (2001) Pyridoxine-induced neuropathy in rats: a sensory neuropathy that responds to 4-methylcatechol. Neurobiol Dis 8:626–635PubMedCrossRef

12.

Cassidy J, Paul J, Soukop M, Habeshaw T, Reed NS, Parkin D, Kaye SB (1998) Clinical trials of nimodipine as a potential neuroprotector in ovarian cancer patients treated with cisplatin. Cancer Chemother Pharmacol 41:161–166PubMedCrossRef

13.

Contreras PC, Vaught JL, Gruner JA, Brosnan C, Steffler C, Arezzo JC, Lewis ME, Kessler JA, Apfel SC (1997) Insulin-like growth factor-I prevents development of a vincristine neuropathy in mice. Brain Res 774:20–26PubMedCrossRef

14.

Creange A, Barlovatz-Meimon G, Gherardi RK (1997) Cytokines and peripheral nerve disorders. Eur Cytokine Netw 8:145–151PubMed

15.

Elson GC, Lelievre E, Guillet C, Chevalier S, Plun-Favreau H, Froger J, Suard I, de Coignac AB, Delneste Y, Bonnefoy JY, Gauchat JF, Gascan H (2000) CLF associates with CLC to form a functional heteromeric ligand for the CNTF receptor complex. Nat Neurosci 3:867–872PubMedCrossRef

16.

Furukawa Y, Fukazawa N, Miyama Y, Hayashi K, Furukawa S (1990) Stimulatory effect of 4-alkylcatechols and their diacetylated derivatives on the synthesis of nerve growth factor. Biochem Pharmacol 40:2337–2342PubMedCrossRef

17.

Furukawa Y, Tomioka N, Sato W, Satoyoshi E, Hayashi K, Furukawa S (1989) Catecholamines increase nerve growth factor mRNA content in both mouse astroglial cells and fibroblast cells. FEBS Lett 247:463–467PubMedCrossRef

18.

Kennel P, Fonteneau P, Martin E, Schmidt JM, Azzouz M, Borg J, Guenet JL, Schmalbruch H, Warter JM, Poindron P (1996) Electromyographical and motor performance study in the pmn model of neurodegenerative disease. Neurobiol Dis 3:137–147PubMedCrossRef

19.

Gadient RA, Otten U (1996) Postnatal expression of interleukin-6 (IL-6) and IL-6 receptor (IL-6R) mRNAs in rat sympathetic and sensory ganglia Brain Res 724:41–46PubMedCrossRef

20.

Haggiag S, Chebath J, Revel M (1999) Induction of myelin gene expression in Schwann cell cultures by an interleukin-6 receptor-interleukin-6 chimera. FEBS Lett 457:200–204PubMedCrossRef

21.

Hama T, Miyamoto M, Tsukui H, Nishio C, Hatanaka H (1989) Interleukin-6 as a neurotrophic factor for promoting the survival of cultured basal forebrain cholinergic neurons from postnatal rats. Neurosci Lett 104:340–344PubMedCrossRef

22.

Hayakawa K, Itoh T, Niwa H, Mutoh T, Sobue G (1998) NGF prevention of neurotoxicity induced by cisplatin, vincristine and Taxol depends on toxicity of each drug and NGF treatment schedule: in vitro study of adult rat sympathetic ganglion explants. Brain Res 794:313–319PubMedCrossRef

23.

Herodin F, Mestries JC, Janodet D, Martin S, Mathieu J, Gascon MP, Pernin MO, Ythier A (1992) Recombinant glycosylated human interleukin-6 accelerates peripheral blood platelet count recovery in radiation-induced bone marrow depression in baboons. Blood 80:688–695PubMed

24.

Hilkens PH, Pronk LC, Verweij J, Vecht CJ, van Putten WL, van den Bent MJ (1997) Peripheral neuropathy induced by combination chemotherapy of docetaxel and cisplatin. Br J Cancer 75:417–422PubMed

25.

Hilkens PH, ven den Bent MJ (1997) Chemotherapy-induced peripheral neuropathy. J Peripher Nerv Syst 2:350–361PubMed

26.

Hirota H, Kiyama H, Kishimoto T, Taga T (1996) Accelerated Nerve Regeneration in Mice by upregulated expression of interleukin (IL) 6 and IL-6 receptor after trauma. J Exp Med 183:2627–2634PubMedCrossRef

27.

Holliday J, Parsons K, Curry J, Lee SY, Gruol DL (1995) Cerebellar granule neurons develop elevated calcium responses when treated with interleukin-6 in culture. Brain Res 673:141–148PubMedCrossRef

28.

Huang H, Zhu L, Reid BR, Drobny GP, Hopkins PB (1995) Solution structure of a cisplatin-induced DNA interstrand cross-link. Science 270:1842–1845PubMedCrossRef

29.

Ikeda K, Iwasaki Y, Shiojima T, Kinoshita M (1996) Neuroprotective effect of various cytokines on developing spinal motoneurons following axotomy. J Neurol Sci 135:109–113PubMedCrossRef

30.

Ikeda K, Kinoshita M, Tagaya N, Shiojima T, Taga T, Yasukawa K, Suzuki H, Okano A (1996) Coadministration of interleukin-6 (IL-6) and soluble IL-6 receptor delays progression of wobbler mouse motor neuron disease. Brain Res 726:91–97PubMedCrossRef

31.

Jarskog LF, Xiao H, Wilkie MB, Lauder JM, Gilmore JH (1997) Cytokine regulation of embryonic rat dopamine and serotonin neuronal survival in vitro. Int J Dev Neurosci 15:711–716PubMedCrossRef

32.

Jones SA, Rose-John S (2002) The role of soluble receptors in cytokine biology: the agonistic properties of the sIL-6R/IL-6 complex. Biochim Biophys Acta 1592:251–263PubMedCrossRef

33.

Kiefer R, Lindholm D, Kreutzberg GW (1993) Interleukin-6 and transforming growth factor-beta 1 mRNAs are induced in rat facial nucleus following motoneuron axotomy. Eur J Neurosci 5:775–781PubMedCrossRef

34.

Kuroi K, Shimozuma K, Taguchi T, Imai H, Yamashiro H, Ohsumi S, Saito S (2005) Pathophysiology of seroma in breast cancer. Breast Cancer 12:288–293PubMedCrossRef

35.

Kushima Y, Hama T, Hatanaka H (1992) Interleukin-6 as a neurotrophic factor for promoting the survival of cultured catecholaminergic neurons in a chemically defined medium from fetal and postnatal rat midbrains. Neurosci Res 13:267–280PubMedCrossRef

36.

Le Quesne PM, Fowler CJ, Harding AE (1985) A study of the effects of isaxonine on vincristine-induced peripheral neuropathy in man and regeneration following peripheral nerve crush in the rat. J Neurol Neurosur Psychiatry 48:933–935CrossRef

37.

Legha SS (1986) Vincristine neurotoxicity. Pathophysiology and management. Med Toxicol 1:421–427PubMed

38.

Lewis ME, Neff NT, Contreras PC, Stong DB, Oppenheim RW, Grebow PE, Vaught JL (1993) Insulin-like growth factor-I: potential for treatment of motor neuronal disorders. Exp Neurol 124:73–88PubMedCrossRef

39.

Li M, Sendtner M, Smith A (1995) Essential function of LIF receptor in motor neurons. Nature 378:724–727PubMedCrossRef

40.

Marz P, Cheng JG, Gadient RA, Patterson PH, Stoyan T, Otten U, Rose-John S (1998) Sympathetic neurons can produce and respond to interleukin 6. Proc Natl Acad Sci USA 95:3251–3256PubMedCrossRef

41.

Matsuda S, Wen TC, Morita F, Otsuka H, Igase K, Yoshimura H, Sakanaka M (1996) Interleukin-6 prevents ischemia-induced learning disability and neuronal and synaptic loss in gerbils. Neurosci Lett 204:109–112PubMedCrossRef

42.

McDonald ES, Randon KR, Knight A, Windebank AJ (2005) Cisplatin preferentially binds to DNA in dorsal root ganglion neurons in vitro and in vivo: a potential mechanism for neurotoxicity. Neurobiol Dis 18:305–313PubMedCrossRef

43.

Mollman JE, Hogan WM, Glover DJ, McCluskey LF (1988) Unusual presentation of cis-platinum neuropathy. Neurology 38:488–490PubMed

44.

Peng YP, Qiu YH, Lu JH, Wang JJ (2005) Interleukin-6 protects cultured cerebellar granule neurons against glutamate-induced neurotoxicity. Neurosci Lett 374:192–196PubMedCrossRef

45.

Postma TJ, Heimans JJ, Muller MJ, Ossenkoppele GJ, Vermorken JB, Aaronson NK (1998) Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy. Ann Oncol 9:739–744PubMedCrossRef

46.

Reichert F, Levitzky R, Rotshenker S (1996) Interleukin 6 in intact and injured mouse peripheral nerves. Eur J Neurosci 8:530–535PubMedCrossRef

47.

Rodriguez M, Pavelko KD, McKinney CW, Leibowitz JL (1994) Recombinant human IL-6 suppresses demyelination in a viral model of multiple sclerosis. J Immunol 153:3811–3821PubMed

48.

Sahenk Z, Barohn R, New P, Mendell JR (1994) Taxol neuropathy. Electrodiagnostic and sural nerve biopsy findings. Arch Neurol 51:726–729PubMed

49.

Saita K, Ohi T, Hanaoka Y, Furukawa S, Furukawa Y, Hayashi K, Matsukura S (1996) A catechol derivative (4-methylcatechol) accelerates the recovery from experimental acrylamide-induced neuropathy. J Pharmacol Exp Ther 276:231–237PubMed

50.

Schafer KH, Mestres P, Marz P, Rose-John S (1999) The IL-6/sIL-6R fusion protein hyper-IL-6 promotes neurite outgrowth and neuron survival in cultured enteric neurons. J Interferon Cytokine Res 19:527–532PubMedCrossRef

51.

Taga T, Kishimoto T (1997) Gp130 and the interleukin-6 family of cytokines. Annu Rev Immunol 15:797–819PubMedCrossRef

52.

Toulmond S, Vige X, Fage D, Benavides J (1992) Local infusion of interleukin-6 attenuates the neurotoxic effects of NMDA on rat striatal cholinergic neurons. Neurosci Lett 144:49–52PubMedCrossRef

53.

Ullmann CD, Scholm J, Greiner JW (1992) Interleukin-6 increases carcinoembryonic antigen and histocompatibility leukocyte antigen expression on the surface of human colorectal carcinoma cells. J Immunother 12:231–241PubMedCrossRef

54.

Wagner JA (1996) Is IL-6 both a cytokine and a neurotrophic factor? J Exp Med 183:2417–2419PubMedCrossRef

55.

Wang MS, Davis AA, Culver DG, Wang Q, Powers JC, Glass JD (2004) Calpain inhibition protects against Taxol-induced sensory neuropathy. Brain 127:671–679PubMedCrossRef

56.

Wang MS, Davis AA, Culver DG, Glass JD (2002) Wlds mice are resistant to paclitaxel (Taxol) neuropathy. Ann Neurol 52:442–447PubMedCrossRef

57.

Yamada M, Hatanaka H (1994) Interleukin-6 protects cultured rat hippocampal neurons against glutamate-induced cell death. Brain Res 643:173–180PubMedCrossRef

58.

Yoshida K, Taga T, Saito M, Suematsu S, Kumanogoh A, Tanaka T, Fujiwara H, Hirata M, Yamagami T, Nakahata T, Hirabayashi T, Yoneda Y, Tanaka K, Wang WZ, Mori C, Shiota K, Yoshida N, Kishimoto T (1996) Targeted disruption of gp130, a common signal transducer for the interleukin 6 family of cytokines, leads to myocardial and hematological disorders. Proc Natl Acad Sci USA 93:407–411PubMedCrossRef

59.

Ziegler D, Reljanovic M, Mehnert H, Gries FA (1999). Alpha-lipoic acid in the treatment of diabetic polyneuropathy in Germany: current evidence from clinical trials. Exp Clin Endocrinol Diabetes 107:421–430PubMedCrossRef

Title: Interleukin-6 protects against paclitaxel, cisplatin and vincristine-induced neuropathies without impairing chemotherapeutic activity
Authors: Noelle Callizot
Emile Andriambeloson
Jonathan Glass
Michel Revel
Pamela Ferro
Rocco Cirillo
Pierre-Alain Vitte
Michel Dreano
Publication date: 01-11-2008
Publisher: Springer-Verlag
Published in: Cancer Chemotherapy and Pharmacology / Issue 6/2008
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-008-0689-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 6/2008

Disruption of microfilaments by cytochalasin B decreases accumulation of cisplatin in human epidermal carcinoma and liver carcinoma cell lines

Inhibition of CD44 expression in hepatocellular carcinoma cells enhances apoptosis, chemosensitivity, and reduces tumorigenesis and invasion

Reversal of P-glycoprotein-mediated multidrug resistance of cancer cells by five schizandrins isolated from the Chinese herb Fructus Schizandrae

Th1/Th2 balance: an important indicator of efficacy for intra-arterial chemotherapy

Is oncogenesis a normal cellular defense mechanism?

Professor Lloyd R. Kelland: man of science

Keynote webinar | Spotlight on antibody–drug conjugates in cancer